NCT01672450View on ClinicalTrials.gov

A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Melanoma
Interventions
DRUG

Intratumoral Ipilimumab and Interleukin-2

Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT01672450 - A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma | Biotech Hunter | Biotech Hunter